News | Cardiac Imaging | May 10, 2024

Enlarged Lymph Nodes on Screening Mammograms Predict Cardiometabolic Disease, Cardiovascular Risk

A, Normal axillary lymph nodes measuring < 1.5 cm in 63-year-old woman with BM = 43.2. B, Fat-enlarged axillary node with large fatty hilum measuring 4.2 cm in 52-year-old woman with BMI = 45.8.

Variable LN morphology on screening mammograms in women with obesity due to ectopic fat deposition. A, Normal axillary lymph nodes measuring < 1.5 cm in 63-year-old woman with BM = 43.2. B, Fat-enlarged axillary node with large fatty hilum measuring 4.2 cm in 52-year-old woman with BMI = 45.8.


May 10, 2024 — According to the Summa Cum Laude Award-Winning Online Poster presented during the 124th ARRS Annual Meeting, fat-enlarged axillary nodes on screening mammograms can predict high cardiovascular disease (CVD) risk, Type 2 diabetes (T2DM), and hypertension (HTN).

“Incorporating fat-enlarged nodes into CVD risk models has the potential to improve CVD risk stratification without additional cost or additional testing,” said Jessica Rubino, MD, from Dartmouth Hitchcock Medical Center in Lebanon, NH. “Fat-enlarged axillary lymph nodes visualized on screening mammography may increase the ability to identify women who would benefit from CVD risk reduction strategies and more intensive risk assessment with coronary artery CT.”

Rubino et al. reviewed patients (women, 40–75 years) without known coronary artery disease who had a routine screening mammogram and cardiovascular risk factors available in the EMR within 1 year of the index mammogram (January 1, 2011–December 31, 2012). Evaluating major adverse cardiovascular events (MACE) within 10 years of the index mammogram, the researchers used clinical parameters at the time of the index mammogram to determine high estimated CVD risk via the pooled cohort equation (PCE) —defined by the American Heart Association as more than a 7.5% likelihood of MACE within 10 years. Two breast imagers evaluated screening mammograms to measure the length of the largest visible axillary LN in each breast in the mediolateral oblique view, analyzing the largest visible node for each patient. Logistic regression then examined associations between lymph node size, 10-year CVD risk, MACE, T2DM, HTN, low density lipoprotein (LDL), age, and BMI.

Ultimately, among 1,216 women included in this ARRS Annual Meeting Summa Cum Laude Scientific Poster, 907 (74.6%) had a visible axillary LN on the index mammogram, and 232 (19.1%) women had fat-enlarged nodes—defined as larger than 20 mm in length due to an expanded fatty hilum. Women with fat-enlarged nodes had a high risk of CVD defined by PCE (OR = 2.6, 95% CI 1.5–4.2), as well as a higher prevalence of T2DM (OR = 4, 95% CI 2.1–7.7) and HTN (OR = 2.5, 95% CI 1.6–4.0). Fat-enlarged nodes were also associated with a trend toward higher risk of MACE (OR = 1.7, 95% CI 0.9–3.1) and LDL (OR = 1.4, 95% CI 0.9–2.1).

“These results support further investigation of fat-enlarged lymph nodes,” Rubino added, “particularly with studies leveraging AI evaluation of mammographic fat-enlarged LNs and cardiometabolic disease.”

For more information: www.arrs.org

Find more ARRS24 conference coverage here


Related Content

News | Heart Failure

July 28, 2026 — Abbott has initiated the Treat TR study, a post-market study of the company’s TriClip transcatheter edge ...

Home July 29, 2026
Home
News | Heart Failure

July 22, 2026 — Ultromics has announced results from an independent clinical data set that shows the company’s EchoGo ...

Home July 22, 2026
Home
News | Heart Failure

June 29, 2026 — A new international expert consensus document refines and updates how heart failure is identified and ...

Home June 30, 2026
Home
News | Heart Failure

May 28, 2026 — Coredio has announced that the U.S. Food and Drug Administration (FDA) has granted its Cardiac ...

Home May 28, 2026
Home
News | Heart Failure

May 10, 2026 — WhiteSwell has announced primary results from the DELTA-HF feasibility clinical trial evaluating the eLym ...

Home May 21, 2026
Home
Feature | Heart Failure | Kyle Hardner

Editor's Note: This is Part Three of a three-part series highlighting several of the presentations from the American ...

Home May 13, 2026
Home
News | Heart Failure

May 10, 2026 — Results from the first randomized trial evaluating microRNA inhibition in heart failure were presented ...

Home May 11, 2026
Home
Feature | Heart Failure | Kyle Hardner

Could a link between the heart, brain and immune system help reduce the occurrence of heart attacks and lessen the ...

Home May 04, 2026
Home
News | Heart Failure

April 21, 2026 — Nuwellis, Inc. has announced a software update to its Aquadex SmartFlow ultrafiltration platform. The ...

Home April 23, 2026
Home
News | Heart Failure

March 28, 2026 — Amgen announced today that Repatha (evolocumab), when added to statins or other low-density lipoprotein ...

Home April 06, 2026
Home
Subscribe Now